MSB 2.17% $1.13 mesoblast limited

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-644

  1. 238 Posts.
    lightbulb Created with Sketch. 518
    I can't wait to see the amazing results for medically refractory Crohn's colitis that were treated by targeted endoscopic delivery of Remestemcel-L

    It just gets better and better for Rem-L

    https://clinicaltrials.gov/ct2/show/NCT04548583
    Last edited by JSBStrikesBack: 16/03/23
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.